COMPARING Y90 DEVICES

Transcription

1 COMPARING Y90 DEVICES William S Rilling MD, FSIR Professor of Radiology and Surgery Director, Vascular and Interventional Radiology Medical College of Wisconsin

2 DISCLOSURES Research support : Siemens, Biocompatibles Consultant B Braun Vascular, Bayer, Nordion, Cook Advisory board : Navilyst, DBO innovations Will be discussing off label use

3

4 Y90 RADIOEMBOLIZATION Critical differences from TACE Requires more advanced case planning Even more critical to identify anatomic variants Less flexibility in technique No or little visual feedback during administration Effects of day of treatment ( number of spheres/dose )

5 BILOBAR DISEASE : TYPICAL TREATMENT ALGORITHM Clinic visit Hepatic angiogram, MAA shunt study, possible embolization of extrahepatic vessels 3D lobar liver volume calculations Dose calculation, device ordered Y90 administration to lobe with dominant disease Clinic, 1 month Dose calculation other lobe Y90 administration to remaining lobe 1 month post imaging, clinic, labs

6 LOGISTICS: Y90 VS TACE Y90 Consult, clinic visit Determine device and HDE,IDE,CU status Obtain IRB/FDA approval for CU Liver volumes Shunt study/embo Shunt analysis and calculations Dose calculations Procedure scheduling Dose ordering Insurance pre- authorization Dose calibration pre-and post Treatment Ave delay from consult to treat: days TACE Consult, clinic visit Insurance pre-certification Treatment Ave delay from consult to treatment: 7 days

7 Y90 DEVICES TheraSphere MDS Nordion, Canada Glass Yttrium-90 Size = 25 microns doses = 3-20 GBq # spheres/tx = mil Specific grav = >2 US FDA HCC approved Dec 1999 SIR-Spheres Sydney, Australia Resin Yttrium-90 Size = 35 microns dose = 3 GBq # spheres/tx = million Specific grav = < 1.8 US FDA colorectal approved March 2002

8 Implantation Procedure: Start IR works B line, AU Works D line Spheres delivered in multiple small aliquots over 20 minutes B line - IR D line - AU

9 TheraSphere System Ready for Assembly

10 IDEAL Y90 DEVICE Reproducible, patient specific dosimetry Easy to order, schedule cases Customize particle load Simple dose calibration Easy to divide doses Safe for personnel handling Simple, complete administration Visual feedback during administration Simple disposal

11 Dis/advantages TheraSphere/Sirspheres TheraSphere Pros: Not embolic, minimal toxicity Can use in portal vein thrombosis or compression Simple dosimetry Shelf-life 14 days Can retreat Independent of tumor burden SIR-Spheres Pros: X-ray guidance Can fractionate dose better suspension, coverage Dependent on tumor burden Lower dose, allows fractionation Courtesy R Salem

12 Yttruim-90 Radioembolization: Is Routine Prophylactic Embolization of Extrahepatic Vessels Necessary? William S. Rilling, MD; Melissa J. Neisen, MD; Robert A. Heib, MD; Eric J. Hohenwalter, MD; Sean M. Tutton, MD Medical College of Wisconsin Affiliated Hospitals March 5, 2007

13 Falciform Artery Embolization HCC Segment 4 Coil embolization of falciform artery

14 GDA Embolization Ocular melanoma Segment 4 Coil embolization GDA

15

16

17 CHOOSING A DEVICE Availability Operator Familiarity Data Approval status Reimbursement Institutional politics Clinical trial availability Tumor burden Tumor vascularity Arterial anatomy Previous therapy Hepatic reserve

18 REGULATORY AND REIMBURSEMENT STATUS Reimbursement status variable Both companies have resources to help Institutional response to regulatory staus is variable Medicare patients sign ABN for TS at MCW

19 CUSTOMIZING THERAPY Tumor coverage : treatment day, device selection Segmental or subsegmental treatment Divided doses : avoiding non target vessels, forcing distribution into target segments Fewer particles in higher risk patients ( PVT, hepatofugal flow, biliary colonization,etc )

20 PRE Y90 CASE 3 Define ROI #1 in normal liver tissue Define ROI #2 & #3 to be in tumors Filled ROIs to examine the ROI curves Rilling W et al SIR 2010

21 Decay Graph ~8 million microspheres/dose ~6 million microspheres/dose ~4 million microspheres/dose ~2.8 million microspheres/dose ~2 million microspheres/dose ~1.2 million microspheres/dose 64.2 hrs

22 LIVER DAMAGE FROM CHEMOTHERAPY 406 patients with CRC mets resected 158 no chemo 248 neoadjuvant chemo 16 week median duration Irinotecan based 23% Oxaliplatin based 20% 8% steatohepatits, significantly associated with irinotecan exposure (OR 5.4) 90 d mortality 14.7% with steatohepatitis vs 1.6% overall (OR 10.5) Vauthey et al J Clin Oncol 2006

23

24 HIGH RISK ANATOMY

25 61 y.o, salvage Rx for CRC mets

26

27

28

29

30 SUMMARY The ideal RE device does not exist TS and SS have important differences Choice of device is complex With two devices and companies working in this field, IO physicians and patients have benefitted